Payment overview · 2025
General Payments
$129,265.75
189 reported records · 22 companies
Healthcare provider profile · identity verified
Brett Bielory, M.D.
Allopathic & Osteopathic Physicians|Ophthalmology · RUTHERFORD, NJ · NPI 1437592946
Verified facts
What the public records show
CMS Open Payments records show Brett Bielory, M.D. received $129,265.75 in general payments during 2025 across 189 reported records.
BIOTISSUE HOLDINGS INC. accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cequa, Miebo, Oxervate, Vyzulta, Xiidra.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EYSUVIS as an associated drug or biological on 4201 records involving 2750 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eysuvis by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rhopressa as an associated drug or biological on 1524 records involving 961 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rhopressa by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Simbrinza as an associated drug or biological on 1563 records involving 637 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Simbrinza by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX as an associated drug or biological on 10 records involving 10 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lotemax by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLENSA as an associated drug or biological on 18 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Prolensa by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYZULTA as an associated drug or biological on 10850 records involving 5317 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Vyzulta by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Xiidra by this doctor in 2024.
Dompe US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OXERVATE as an associated drug or biological on 19540 records involving 9712 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Oxervate by this doctor in 2024.
Harrow Eye, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FLAREX as an associated drug or biological on 39 records involving 37 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Flarex by this doctor in 2024.
Harrow Eye, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TOBRADEX ST as an associated drug or biological on 50 records involving 48 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tobradex St by this doctor in 2024.
SUN PHARMACEUTICAL INDUSTRIES INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cequa as an associated drug or biological on 25765 records involving 9461 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Cequa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $40,531.72 | 31.4% | 35 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $35,821.64 | 27.7% | 27 | 2025 |
| Rayner Intraocular Lenses Limited | Unresolved — no canonical attribution shown | $19,286.30 | 14.9% | 14 | 2025 |
| TOPCON HEALTHCARE, INC. | Unresolved — no canonical attribution shown | $18,016.89 | 13.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $8,539.40 | 6.6% | 12 | 2025 |
| Carl Zeiss Meditec, Inc. | Unresolved — no canonical attribution shown | $2,550.00 | 2.0% | 1 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2,131.13 | 1.6% | 17 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $701.39 | 0.5% | 31 | 2025 |
| Sight Sciences, Inc. | Unresolved — no canonical attribution shown | $377.45 | 0.3% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $234.08 | 0.2% | 8 | 2025 |
| Glaukos Corporation | Unresolved — no canonical attribution shown | $207.37 | 0.2% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $161.89 | 0.1% | 2 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $151.69 | 0.1% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $140.00 | 0.1% | 1 | 2025 |
| Topcon Healthcare, Inc. | Unresolved — no canonical attribution shown | $129.90 | 0.1% | 1 | 2025 |
| Haag-Streit USA, Inc. | Unresolved — no canonical attribution shown | $89.79 | 0.1% | 1 | 2025 |
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $55.60 | 0.0% | 2 | 2025 |
| LENSAR, Inc. | Unresolved — no canonical attribution shown | $42.22 | 0.0% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $34.80 | 0.0% | 2 | 2025 |
| Beaver-Visitec International, Inc. | Unresolved — no canonical attribution shown | $32.95 | 0.0% | 1 | 2025 |
| Ocular Therapeutix, Inc. | Unresolved — no canonical attribution shown | $15.23 | 0.0% | 1 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $14.31 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $77,500.00 | 16 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $26,100.00 | 4 |
| Compensation for serving as faculty or as a speaker for a medical education program | $8,500.00 | 2 |
| Travel and Lodging | $7,611.09 | 28 |
| Honoraria | $5,000.00 | 1 |
| Food and Beverage | $4,554.66 | 138 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROKERA Normalized: prokera |
Device | BIOTISSUE HOLDINGS INC. | $31,821.72 | 28 | 2025 |
Source payment records
|
|||||
| RayOne Aspheric Normalized: rayone aspheric |
Device | Rayner Intraocular Lenses Limited | $19,272.97 | 13 | 2025 |
Source payment records
|
|||||
| RayOne EMV Normalized: rayone emv |
Device | Rayner Intraocular Lenses Limited | $19,272.97 | 13 | 2025 |
Source payment records
|
|||||
| RayOne Spheric Normalized: rayone spheric |
Device | Rayner Intraocular Lenses Limited | $19,272.97 | 13 | 2025 |
Source payment records
|
|||||
| enVista Envy IOL Normalized: envista envy iol |
Device | Bausch & Lomb Americas Inc. | $18,834.01 | 6 | 2025 |
Source payment records
|
|||||
| enVista MX60 IOL Normalized: envista mx60 iol |
Device | Bausch & Lomb Americas Inc. | $8,804.23 | 8 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $8,539.40 | 12 | 2025 |
Source payment records
|
|||||
| AMNIOGRAFT Normalized: amniograft |
Medical Supply | BIOTISSUE HOLDINGS INC. | $5,425.00 | 1 | 2025 |
Source payment records
|
|||||
| CALLISTO eye Normalized: callisto eye |
Device | Carl Zeiss Meditec, Inc. | $2,550.00 | 1 | 2025 |
Source payment records
|
|||||
| CIRRUS HD-OCT Normalized: cirrus hd oct |
Device | Carl Zeiss Meditec, Inc. | $2,550.00 | 1 | 2025 |
Source payment records
|
|||||
| IOLMaster 700 Normalized: iolmaster 700 |
Device | Carl Zeiss Meditec, Inc. | $2,550.00 | 1 | 2025 |
Source payment records
|
|||||
| MEL 90 Normalized: mel 90 |
Device | Carl Zeiss Meditec, Inc. | $2,550.00 | 1 | 2025 |
Source payment records
|
|||||
| VisuMax Normalized: visumax |
Device | Carl Zeiss Meditec, Inc. | $2,550.00 | 1 | 2025 |
Source payment records
|
|||||
| AMNIOGRAFT/AMNIOGUARD Normalized: amniograft amnioguard |
Medical Supply | BIOTISSUE HOLDINGS INC. | $2,325.00 | 1 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $701.39 | 31 | 2025 |
Source payment records
|
|||||
| OMNI SURGICAL SYSTEM Normalized: omni surgical system |
Device | Sight Sciences, Inc. | $377.45 | 15 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $331.13 | 16 | 2025 |
Source payment records
|
|||||
| SION SURGICAL INSTRUMENT Normalized: sion surgical instrument |
Device | Sight Sciences, Inc. | $315.51 | 12 | 2025 |
Source payment records
|
|||||
| RAYNER CATARACT SET 1 Normalized: rayner cataract set 1 |
Device | Rayner Intraocular Lenses Limited | $271.92 | 5 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $207.18 | 5 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $183.37 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $161.89 | 2 | 2025 |
Source payment records
|
|||||
| Izervay Normalized: izervay |
Drug | Astellas Pharma US Inc | $140.00 | 1 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $83.44 | 7 | 2025 |
Source payment records
|
|||||
| STELLARIS ELITE Normalized: stellaris elite |
Device | Bausch & Lomb Americas Inc. | $42.43 | 1 | 2025 |
Source payment records
|
|||||
| LENSAR LASER SYSTEM Normalized: lensar laser system |
Device | LENSAR, Inc. | $42.22 | 1 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $40.32 | 4 | 2025 |
Source payment records
|
|||||
| Tecnis Simplicity Normalized: tecnis simplicity |
Device | Johnson & Johnson Surgical Vision, Inc. | $37.42 | 1 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $31.26 | 3 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $26.90 | 3 | 2025 |
Source payment records
|
|||||
| iDoseTR Normalized: idosetr |
Drug | Glaukos Corporation | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| iStent infinite Normalized: istent infinite |
Device | Glaukos Corporation | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| CATALYS SYSTEM Normalized: catalys system |
Device | Johnson & Johnson Surgical Vision, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| TECNIS IOL Normalized: tecnis iol |
Device | Johnson & Johnson Surgical Vision, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| DEXTENZA Normalized: dextenza |
Drug | Ocular Therapeutix, Inc. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $14.57 | 5 | 2025 |
Source payment records
|
|||||
| Rocklatan Normalized: rocklatan |
Drug | Alcon Vision LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| Omidria Normalized: omidria |
Drug | Rayner Intraocular Lenses Limited | $13.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Cequa cequa |
2025 | Cequa | 2024 | 34 | exact normalized | Medicare Part D |
| MIEBO miebo |
2025 | Miebo | 2024 | 136 | exact normalized | Medicare Part D |
| OXERVATE oxervate |
2025 | Oxervate | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYZULTA vyzulta |
2025 | Vyzulta | 2024 | 30 | exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | EYSUVIS open payments reported associated product |
CMS Open Payments — General Payments 4201 supporting records · 2750 recipient NPIs · example record 1207357018 |
Eysuvis · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | Rhopressa open payments reported associated product |
CMS Open Payments — General Payments 1524 supporting records · 961 recipient NPIs · example record 1207357314 |
Rhopressa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | Simbrinza open payments reported associated product |
CMS Open Payments — General Payments 1563 supporting records · 637 recipient NPIs · example record 1207357100 |
Simbrinza · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX open payments reported associated product |
CMS Open Payments — General Payments 10 supporting records · 10 recipient NPIs · example record 1254762767 |
Lotemax · 2024 Exact normalized brand match · 1 Part D row |
28 | 19 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
136 | 51 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | PROLENSA open payments reported associated product |
CMS Open Payments — General Payments 18 supporting records · 13 recipient NPIs · example record 1254766966 |
Prolensa · 2024 Exact normalized brand match · 1 Part D row |
26 | 20 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | VYZULTA open payments reported associated product |
CMS Open Payments — General Payments 10850 supporting records · 5317 recipient NPIs · example record 1254730226 |
Vyzulta · 2024 Exact normalized brand match · 1 Part D row |
30 | 13 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
43 | 26 |
| Dompe US, Inc. Exact reporting entity; no affiliate inference |
2025 | OXERVATE open payments reported associated product |
CMS Open Payments — General Payments 19540 supporting records · 9712 recipient NPIs · example record 1248849978 |
Oxervate · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Harrow Eye, LLC Exact reporting entity; no affiliate inference |
2025 | FLAREX open payments reported associated product |
CMS Open Payments — General Payments 39 supporting records · 37 recipient NPIs · example record 1236210819 |
Flarex · 2024 Exact normalized brand match · 1 Part D row |
16 | 13 |
| Harrow Eye, LLC Exact reporting entity; no affiliate inference |
2025 | TOBRADEX ST open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 48 recipient NPIs · example record 1236210819 |
Tobradex St · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. Exact reporting entity; no affiliate inference |
2025 | Cequa open payments reported associated product |
CMS Open Payments — General Payments 25765 supporting records · 9461 recipient NPIs · example record 1250962431 |
Cequa · 2024 Exact normalized brand match · 1 Part D row |
34 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Miebo | Perfluorohexyloctane/Pf | 136 | 51 |
| Prednisolone Acetate | Prednisolone Acetate | 117 | 83 |
| Restasis | Cyclosporine | 101 | 36 |
| Cyclosporine | Cyclosporine | 69 | 34 |
| Moxifloxacin | Moxifloxacin Hcl | 60 | 41 |
| Xiidra | Lifitegrast | 43 | 26 |
| Cequa | Cyclosporine | 34 | 16 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 31 | suppressed |
| Vyzulta | Latanoprostene Bunod | 30 | 13 |
| Latanoprost | Latanoprost | 28 | 13 |
| Lotemax | Loteprednol Etabonate | 28 | 19 |
| Prolensa | Bromfenac Sodium | 26 | 20 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 22 | 18 |
| Fluorometholone | Fluorometholone | 17 | 15 |
| Bepotastine Besilate | Bepotastine Besilate | 16 | suppressed |
| Eysuvis | Loteprednol Etabonate | 16 | 15 |
| Flarex | Fluorometholone Acetate | 16 | 13 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 15 | suppressed |
| Bromfenac Sodium | Bromfenac Sodium | 14 | 11 |
| Simbrinza | Brinzolamide/Brimonidine Tart | 14 | suppressed |
| Tafluprost | Tafluprost/Pf | 14 | suppressed |
| Tyrvaya | Varenicline Tartrate | 14 | suppressed |
| Oxervate | Cenegermin-Bkbj | 13 | suppressed |
| Restasis Multidose | Cyclosporine | 13 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Tobradex St | Tobramycin/Dexamethasone | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129,265.75 · 189 records | BIOTISSUE HOLDINGS INC. | ACTHAR, AMNIOGRAFT, AMNIOGRAFT/AMNIOGUARD, CALLISTO eye, CATALYS SYSTEM, CIRRUS HD-OCT, Cequa, DEXTENZA, DURYSTA, IOLMaster 700, Izervay, LENSAR LASER SYSTEM, LUMIGAN, MEL 90, MIEBO, OMNI SURGICAL SYSTEM, OXERVATE, Omidria, PROKERA, Photrexa Viscous and Photrexa, RAYNER CATARACT SET 1, RayOne Aspheric, RayOne EMV, RayOne Spheric, Rocklatan, SION SURGICAL INSTRUMENT, STELLARIS ELITE, TECNIS IOL, TEPEZZA, Tecnis Simplicity, VEVYE, VYZULTA, VisuMax, XDEMVY, XIIDRA, enVista Envy IOL, enVista MX60 IOL, iDoseTR, iStent infinite | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cequa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alcon Vision LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error